| 1. |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
|
| 2. |
Criner GJ, Sue R, Wright S, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018, 198(9): 1151-1164.
|
| 3. |
Labarca G, Uribe JP, Pacheco C, et al. Bronchoscopic lung volume reduction with endobronchial Zephyr valves for severe emphysema: a systematic review and meta-analysis. Respiration, 2019, 98(3): 268-278.
|
| 4. |
Klooster K, van Dijk M, Koster TD, et al. First in human experience of the performance of the new 5.5-LP size Zephyr endobronchial valve. Respiration, 2020, 99(1): 50-55.
|
| 5. |
Herth FJF, Slebos DJ, Criner GJ, et al. Endoscopic lung volume reduction: an expert panel recommendation - update 2019. Respiration, 2019, 97(6): 548-557.
|
| 6. |
Valipour A, Slebos DJ, Herth F, et al. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med, 2016, 194(9): 1073-1082.
|
| 7. |
Rabin AS, Keyes CM, Oberg CL, et al. Emerging interventional pulmonary therapies for chronic obstructive pulmonary disease. J Thorac Imaging, 2019, 34(4): 248-257.
|
| 8. |
Li S, Wang G, Wang C, et al. The REACH trial: a randomized controlled trial assessing the safety and effectiveness of the Spiration® Valve System in the treatment of severe emphysema. Respiration, 2019, 97(5): 416-427.
|
| 9. |
Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogenous emphysema with the Spiration Valve System (EMPROVE). A multicenter, open-label randomized controlled clinical trial. Am J Respir Crit Care Med, 2019, 200(11): 1354-1362.
|
| 10. |
Shah PL, Zoumot Z, Singh S, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med, 2013, 1(3): 233-240.
|
| 11. |
Deslée G, Mal H, Dutau H, et al. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical trial. JAMA, 2016, 315(2): 175-184.
|
| 12. |
Sciurba FC, Criner GJ, Strange C, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW randomized clinical trial. JAMA, 2016, 315(20): 2178-2189.
|
| 13. |
Hartman JE, Klooster K, Gortzak K, et al. Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. Respirology, 2015, 20(2): 319-326.
|
| 14. |
Zoumot Z, Kemp SV, Singh S, et al. Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross-over results from a randomised controlled trial. PLoS One, 2015, 10(4): e0122656.
|
| 15. |
Slebos DJ, Hartman JE, Klooster K, et al. Bronchoscopic coil treatment for patients with severe emphysema: a meta-analysis. Respiration, 2015, 90(2): 136-145.
|
| 16. |
Garner JL, Kemp SV, Srikanthan K, et al. 5-Year Survival after endobronchial coil implantation: secondary analysis of the first randomised controlled trial, RESET. Respiration, 2020, 99(2): 154-162.
|
| 17. |
侯刚. 不同表型慢性阻塞性肺疾病的介入呼吸病学治疗. 临床内科杂志, 2018, 35(11): 736-739.
|
| 18. |
Herth FJ, Valipour A, Shah PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med, 2016, 4(3): 185-193.
|
| 19. |
Gompelmann D, Eberhardt R, Schuhmann M, et al. Lung volume reduction with vapor ablation in the presence of incomplete fissures: 12-month results from the STEP-UP randomized controlled study. Respiration, 2016, 92(6): 397-403.
|
| 20. |
Gompelmann D, Shah PL, Valipour A, et al. Bronchoscopic thermal vapor ablation: best practice recommendations from an expert panel on endoscopic lung volume reduction. Respiration, 2018, 95(6): 392-400.
|
| 21. |
Valipour A. Bronchoscopic thermal vapour Ablation: hot stuff to treat emphysema patients!. Arch Bronconeumol, 2017, 53(1): 1-2.
|
| 22. |
史静宇, 朱辉, 杨赛, 等. 经支气管镜热蒸汽肺减容术的适应证. 国际呼吸杂志, 2020, 40(7): 546-550.
|
| 23. |
Audrit KJ, Delventhal L, Aydin Ö, et al. The nervous system of airways and its remodeling in inflammatory lung diseases. Cell Tissue Res, 2017, 367(3): 571-590.
|
| 24. |
Hummel JP, Mayse ML, Dimmer S, et al. Physiologic and histopathologic effects of targeted lung denervation in an animal model. J Appl Physiol (1985), 2019, 126(1): 67-76.
|
| 25. |
Kistemaker LE, Slebos DJ, Meurs H, et al. Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J, 2015, 46(5): 1489-1492.
|
| 26. |
Slebos DJ, Klooster K, Koegelenberg CF, et al. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax, 2015, 70(5): 411-419.
|
| 27. |
Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2163-2172.
|
| 28. |
Valipour A, Shah PL, Pison C, et al. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. Respiration, 2019, 98(4): 329-339.
|
| 29. |
Pison C, Shah PL, Slebos DJ, et al. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. Respir Res, 2021, 22(1): 62.
|
| 30. |
Slebos DJ, Shah PL, Herth FJ, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am J Respir Crit Care Med, 2019, 200(12): 1477-1486.
|
| 31. |
Valipour A, Shah PL, Herth FJ, et al. Two-Year outcomes for the double-blind, randomized, sham-controlled study of targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2807-2816.
|
| 32. |
Srikanthan K, Kistemaker L, Slebos DJ, et al. Targeted lung denervation modulates the bronchial epithelial transcriptome in COPD. Eur Respir J, 2019, 54 Suppl. 63: OA5169.
|
| 33. |
Slebos DJ, Degano B, Valipour A, et al. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3). BMC Pulm Med, 2020, 20(1): 41.
|
| 34. |
Wang K, Sun J, Gao W, et al. Feasibility, effectiveness, and safety of a novel cryo-balloon targeted lung denervation technique in an animal model. Cryobiology, 2020, 93: 27-32.
|
| 35. |
Moore RF, Lile DJ, Abbas AE. Current status of spray cryotherapy for airway disease. J Thorac Dis, 2017, 9(Suppl 2): S122-S129.
|
| 36. |
Mulcahey TI, Coad JE, Fan WL, et al. Metered Cryospray™: a novel uniform, controlled, and consistent in vivo application of liquid nitrogen cryogenic spray. Med Devices (Auckl), 2017, 10: 29-41.
|
| 37. |
Slebos DJ, Breen D, Coad J, et al. Safety and histological effect of liquid nitrogen metered spray cryotherapy in the lung. Am J Respir Crit Care Med, 2017, 196(10): 1351-1352.
|
| 38. |
Duan H, Li X, Long X, et al. Safety, feasibility, and effectiveness of a novel spray cryotherapy technique in a canine model. Clin Transl Med, 2021, 11(2): e315.
|
| 39. |
Valipour A, Fernandez-Bussy S, Ing AJ, et al. Bronchial rheoplasty for treatment of chronic bronchitis. Twelve-month results from a multicenter clinical trial. Am J Respir Crit Care Med, 2020, 202(5): 681-689.
|
1/5
WeChat